Pancreatic Cancer Research

ResearcherNanjing Medical UniversityNo recent work listed

Dan Fang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3811-3604; OpenAlex author ID A5091720344. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

  1. PKCι Is a Promising Prognosis Biomarker and Therapeutic Target for Pancreatic Cancer. First author DOI 10.1159/000521588↗
  2. S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. Co-author DOI 10.1007/s10565-020-09574-w↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alaa Abdelatty · 2 shared papers, 2021–2022 · strength 0.28
  2. Hongping Xia · 2 shared papers, 2021–2022 · strength 0.28
  3. Xiao Mo · 1 shared paper, 2021 · strength 0.12
  4. Linhua Lan · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.